Samsung Biologics Q3 2026 Results confirm another quarter of strong growth for the Incheon-based contract development and manufacturing organization (KRX: 207940.KS). The company reported revenue of KRW 1,490 billion and operating profit of KRW 640 billion for the third quarter of fiscal year 2026. It announced the figures on October 21, 2026, and raised its 2026 revenue growth guidance to 20%.
According to the company’s press release, the quarter was supported by Plants 1 through 4 operating at full capacity and growing contributions from Plant 5 as production ramps up. The Rockville manufacturing facility in Maryland, U.S., also contributed to revenue. The release describes this as its initial contribution following the acquisition. The Samsung Biologics Q3 2026 Results also show cumulative contract orders exceeding USD 21.9 billion, which the company cites as evidence of sustained demand.
John Rim, President and CEO of Samsung Biologics, said consistent execution across manufacturing programs is ever more important as global pharmaceutical pipelines grow more diverse and supply requirements more complex. He said the company is expanding manufacturing capacity, multi-modality capabilities and global operations. His stated priority is turning those investments into sustainable growth through “disciplined execution.” This is management’s own view, not independent analysis.
Samsung Biologics Q3 2026 Results: Financial Highlights and Year-Over-Year Performance
Consolidated CDMO revenue reached KRW 1,490.3 billion, up KRW 232.8 billion from KRW 1,257.5 billion in the third quarter of 2025. By BiotechReality’s calculation, that is roughly 18.5% year-over-year growth. Operating profit rose to KRW 640.1 billion from KRW 633.5 billion, an increase of KRW 6.6 billion.
EBITDA climbed to KRW 751.5 billion from KRW 728.9 billion, a gain of KRW 22.6 billion. Profit grew far more slowly than sales in the Samsung Biologics Q3 2026 Results. Our calculation puts the operating margin at about 43.0%, against about 50.4% a year earlier. The EBITDA margin comes to about 50.4%, against about 58.0%. The press release does not discuss the reason for the margin change, so the cause is not disclosed.
Consolidated Earnings for CDMO Business (KRW billion, reported by company)
| Metric | Q3 2026 | Q3 2025 | YoY Change |
|---|---|---|---|
| Revenue | 1,490.3 | 1,257.5 | +232.8 |
| Operating Profit | 640.1 | 633.5 | +6.6 |
| EBITDA | 751.5 | 728.9 | +22.6 |
Derived Growth and Margin Metrics (calculated by BiotechReality from Table 1; not reported by the company)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue growth YoY | 18.5% | Not applicable | Not applicable |
| Operating profit growth YoY | 1.0% | Not applicable | Not applicable |
| EBITDA growth YoY | 3.1% | Not applicable | Not applicable |
| Operating margin | 43.0% | 50.4% | Lower |
| EBITDA margin | 50.4% | 58.0% | Lower |
Samsung Biologics Q3 2026 Results: Plant 5 Ramp-Up and Rockville Operations
Capacity is the central operational story in the Samsung Biologics Q3 2026 Results. The company said Plants 1 through 4 are running at full capacity, while Plant 5 contributes more as production ramps up. The release does not quantify Plant 5 output or utilization, so those details are Not disclosed.
The Rockville facility in Maryland delivered its first revenue contribution in the quarter. Samsung Biologics said it maintained stable manufacturing operations and workforce capabilities at the site. It is also evaluating ways to optimize the facility for a broader range of client requirements. Combined with operations at Songdo, Rockville widens the company’s geographic manufacturing presence and its ability to serve U.S. and global demand, as the Samsung Biologics Q3 2026 Results make clear.
Execution is anchored in the company’s ExellenS™ framework. The company describes it as built on standardized facility designs, processes and digital technologies that support consistency and manufacturing readiness across its network. Samsung Biologics also opened a sales office in the Netherlands to strengthen engagement with European pharmaceutical and biotechnology companies.
Samsung Biologics Q3 2026 Results: 2026 Guidance, PolyPeptide Acquisition and KRW 3 Trillion Rights Offering
Guidance is the main forward-looking item in the Samsung Biologics Q3 2026 Results. The company raised its 2026 annual revenue growth guidance to 20%, up from a previous range of 15–20%. This is a forward-looking statement, and actual results may differ from it.
In October, Samsung Biologics published interim results of the PolyPeptide Group public tender offer. It reported that the acceptance offer condition was met with an 87.92% participation rate. The planned acquisition would extend the company’s services into peptide-based therapeutics, complementing its existing antibody and conjugate capabilities. PolyPeptide operates across Europe, the U.S. and India. The Samsung Biologics Q3 2026 Results do not disclose the purchase price or closing timeline, so both are Not disclosed.
To fund strategic investments, including the planned PolyPeptide acquisition and future manufacturing capacity expansion, the company announced a KRW 3 trillion rights offering. Existing shareholder subscriptions are scheduled for November, followed by a general public offering of any unsubscribed shares. Investors tracking the Samsung Biologics Q3 2026 Results should watch the company’s public disclosures for final terms.
Samsung Biologics Q3 2026 Results: MSCI ESG Rating and Sustainability Progress
On sustainability, Samsung Biologics received an “A” rating in the latest MSCI ESG Ratings assessment. It also established a greenhouse gas emissions calculation system to improve emissions data management. The company says the system strengthens its readiness for upcoming mandatory ESG disclosure requirements. The release gives no emissions figures, so quantitative data is Not disclosed.
Looking ahead, the company said it remains focused on operational performance and disciplined implementation of strategic investments. It also plans to strengthen capabilities across an expanding range of modalities and geographic markets. For biopharma sponsors and investors, the Samsung Biologics Q3 2026 Results indicate sustained demand, rising capacity and a widening service portfolio. They also show profit growing more slowly than revenue, which merits attention in coming quarters.
